Aurobindo Recalls MARBETA L KIT Vials Due to Particulate Matter
Aurobindo Pharma USA Inc. is recalling 88,600 vials of MARBETA L KIT because one vial was found to contain a hair.
The agency’s classification
FDA (Drugs): Class I
Class I is a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 per the rubric.
Plain-English summary
Aurobindo Pharma USA Inc. is recalling 88,600 vials of MARBETA L KIT (Lot CLC180117, Exp. June 2021). The recall was initiated because one vial was found to contain a hair, which constitutes the presence of particulate matter.
The affected product is Lidocaine HCl Injection, USP 1 % 50 mg/5 mL (10 mg/mL), 5mL vial. The product is being held at distributor sites in Mexico, Asheboro, NC, Charlotte, NC, and Santa Teresa, NM, and has not been further distributed in the U.S. market.
Consumers and healthcare providers should check their inventory for this specific lot number and expiration date. If the product is found, it should be quarantined and not used.
The recalled product
- Product
- MARBETA L KIT (BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE, LIDOCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE, POVIDINE IODINE, ISOPROPYL ALCOHOL)
- Brand
- MARBETA L KIT
- Manufacturer
- Aurobindo Pharma USA Inc.
- Category
- Drug — Injection
- Affected units
- 88,600
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: CLC180117
- Exp. June 2021
Distribution
Distribution scope not specified by the agency.
Related recalls
Same manufacturer · Aurobindo Pharma USA Inc.
See all →- ModerateDicyclomine Hydrochloride Capsules Recalled for Empty Capsules
FDA (Drugs) · 2026-08-12
- ModerateAmazon Basic Care Acetaminophen 325 mg Tablets Recalled Due to Discoloration
FDA (Drugs) · 2025-06-25
- HighPrescription drug recall: Aurobindo Nebivolol tablets contain excess nitrosamine impurity
FDA (Drugs) · 2024-12-25
- HighPrescription Cinacalcet Tablets Recalled for N-Nitroso Impurity
FDA (Drugs) · 2024-12-11
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding FDA Safety Limit
FDA (Drugs) · 2024-12-11
Same hazard · particulate matter
See all →- ModerateIMAAVY Injection Recalled for Presence of Particulate Matter
FDA (Drugs) · 2026-10-14
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls Plum Administration Sets Due to Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
- HighICU Medical Recalls IV Sets with Potential Drip Chamber Discoloration
FDA (Devices) · 2026-09-23
Similar recalls
- SevereAuroMedics Recalls MARLIDO KIT Vials Due to Foreign Material Presence
FDA (Drugs) · 2019-12-04
- SeverePolymyxin B for Injection Recalled Due to Particulate Matter Contamination
FDA (Drugs) · 2022-02-16
- LowAuroMedics Recalls Amiodarone Hydrochloride Injection Due to Visible Particulate Matter
FDA (Drugs) · 2019-12-04
- CriticalAurobindo Recalls Ampicillin and Sulbactam Injection Due to Glass Particulates
FDA (Drugs) · 2018-02-14
- ModerateFDA Recalls Xylocaine Injections Due to Hair Contamination
FDA (Drugs) · 2026-07-29
- HighXylocaine Injection Recall Due to Hair Contamination
FDA (Drugs) · 2026-07-29